Remimazolam

DB12404ApprovedInvestigationalSmall moleculeBenzodiazepines and benzodiazepine derivatives

Remimazolam is an ultra short-acting benzodiazepine used for the induction and maintenence of procedural sedation during short procedures. Recent trends in anesthesia-related drug development have touted the benefits of so-called "soft drugs" - these agents, such as remifentanil, are designed to be metabolically fragile and thus susceptible to rapid biotransformation and elimination as...

Chemical structure of Remimazolam
Mechanism
Curator reviewed · 2 references
Primary indication
Remimazolam is indicated for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less.Curator reviewed · 2 structured indications
Formula / weight
C21H19BrN4O2 · 439.313 g/mol (avg)
First approval
United States, 2020 · European Union, 2021
Code names
CNS-7056 · ONO-2745 · WHO 9232
Brand names
  • Byfavo

Resolves to

Structure
InChIKeyCYHWMBVXXDIZNZ-KRWDZBQOSA-NSMILESCOC(=O)CC[C@@H]1N=C(C2=CC=CC=N2)C2=CC(Br)=CC=C2N2C(C)=CN=C12

What you can answer from here — as of September 23, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
721Drug interactionsStructured to mechanism, not free text
Sign in
262Clinical trialsPhase, status and sponsor resolved per trial
Sign in
2Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
1ContraindicationEach with its own population and attribute set
Sign in
5Marketed productsAcross 3 countries and 3 labellers
Sign in
1ATC codeIncluding every combination product, plus 11 drug categories
Sign in
18+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Remimazolam, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account